Compare Sana Biotechnology Inc (SANA) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs VICI Properties Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while VICI Properties Inc trades at $26.59 (market cap $29.55B). The key difference: VICI Properties Inc is far larger — about 33.8× Sana Biotechnology Inc's market cap, and VICI Properties Inc pays a 6.71% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | VICI | |
|---|---|---|
Market Cap | $873.84M | $29.55B |
Sector | Health | Real Estate |
52-Week High | $5.92 | $33.93 |
52-Week Low | $2.68 | $25.94 |
Enterprise Value | $848.03M | $46.77B |
Dividend Yield | — | 6.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
VICI Properties trades at $26.83, down 0.15% on the day, with technical indicators showing a neutral bias. The REIT maintains strong fundamentals with a 76.83% net income margin and consistent earnings beats in three of the last four quarters. Recent news highlights institutional buying interest and dividend sustainability discussions amid sector volatility.
VICI offers a compelling value proposition with a 6.7% dividend yield and 36% upside to the consensus price target of $30.00. Key risks include tenant concentration with Caesars/MGM accounting for 70% of rent and macroeconomic sensitivity. Wall Street remains bullish with 77% buy ratings supporting long-term income growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
